ABEONA THERAPEUTICS INC. (37)

Browse by Contract Category

Contracts

Securities Purchase Agreement dated November 3, 2022 (Filed With SEC on November 3, 2022)
License Agreement by and between Abeona Therapeutics Inc. and Ultragenyx Pharmaceutical Inc., dated May 16, 2022 (Filed With SEC on August 11, 2022)
Letter Agreement, dated February 28, 2022, between the Company and Joseph Vazzano (Filed With SEC on May 13, 2022)
Settlement Agreement and Mutual Release, dated November 12, 2021, between the Company and REGENXBIO Inc (Filed With SEC on March 31, 2022)
Form of Registration Rights Agreement (Filed With SEC on November 3, 2022)
Form of Pre-Funded Warrant (Filed With SEC on November 3, 2022)
Form of Warrant (Filed With SEC on November 3, 2022)
Form of Registration Rights Agreement by and among Abeona Therapeutics Inc. and the investors named therein, dated April 29, 2022 (Filed With SEC on May 2, 2022)
Form of Securities Purchase Agreement between Abeona Therapeutics Inc. and the investors thereto, dated April 29, 2022 (Filed With SEC on May 2, 2022)
Letter Agreement, dated October 6, 2021, between the Company and Vishwas Seshadri (Filed With SEC on March 31, 2022)
Letter Agreement, dated September 16, 2021, between the Company and Brendan OMalley (Filed With SEC on March 31, 2022)
Form of Warrant (Filed With SEC on December 17, 2021)
Underwriting Agreement, dated December 17, 2021 (Filed With SEC on December 17, 2021)
Amendment No. 1 to Open Market Sale Agreement, dated November 19, 2021, amending the Open Market Sale Agreement, by and between the Company and Jefferies LLC, dated August 17, 2018 (Filed With SEC on November 19, 2021)
Letter Agreement, dated August 10, 2021, between the Company and Edward Carr (Filed With SEC on November 15, 2021)
Letter Agreement, dated March 19, 2021, between the Company and Michael Amoroso (Filed With SEC on May 17, 2021)
Amended and Restated Letter Agreement, dated January 27, 2021, between the Company and Michael Amoroso (Filed With SEC on May 17, 2021)
Letter Agreement, dated October 26, 2020, between Abeona Therapeutics Inc. and Michael Amoroso (Filed With SEC on October 30, 2020)
Form of Indemnification Agreement (Filed With SEC on October 16, 2020)
Amendment No. 3, dated April 14, 2020, to Letter Agreement, dated January 2, 2020, between the Company and Steven H. Rouhandeh (Filed With SEC on August 10, 2020)
Offer Letter between Abeona Therapeutics Inc. and Edward Carr, dated June 18, 2020 (Filed With SEC on June 23, 2020)
Amendment No. 2, dated March 31, 2020, to Letter Agreement, dated January 2, 2020, between the Company and Steven H. Rouhandeh (Filed With SEC on May 6, 2020)
Letter Agreement, dated March 13, 2020, between the Company and Christine Berni Silverstein (Filed With SEC on May 6, 2020)
Amendment No. 1, dated March 6, 2020, to Letter Agreement, dated January 2, 2020, between the Company and Steven H. Rouhandeh (Filed With SEC on May 6, 2020)
Letter Agreement, dated January 2, 2020, between the Company and Steven H. Rouhandeh (Filed With SEC on May 6, 2020)
Offer Letter, dated April 15, 2020, between Abeona Therapeutics Inc. and Brian J.G. Pereira, M.D (Filed With SEC on April 21, 2020)
Description of Capital Stock of Abeona Therapeutics Inc (Filed With SEC on March 16, 2020)
Letter Agreement regarding Certain Purchaser Rights, dated December 20, 2019, among the Company, Biomedical Value Fund, L.P., Biomedical Offshore Value Fund, Ltd., and GEF-SMA, L.P (Filed With SEC on December 23, 2019)
Form of Pre-Funded Warrant (Filed With SEC on December 23, 2019)
Underwriting Agreement, dated December 20, 2019, among the Company, Jefferies LLC and SVB Leerink LLC (Filed With SEC on December 23, 2019)
Letter Agreement, dated September 12, 2019, amending Offer Letter between the Company and Joo Siffert, M.D., dated February 11, 2019 (Filed With SEC on November 12, 2019)
First Amendment to License Agreement, dated November 1, 2019, between the Company and REGENXBIO Inc (Filed With SEC on November 12, 2019)
Letter Agreement, dated September 12, 2019, amending Offer Letter between the Company and Edward Carr, dated November 9, 2018 (Filed With SEC on November 12, 2019)
Letter Agreement, dated September 12, 2019, amending Offer Letter between the Company and Christine Berni Silverstein, dated January 8, 2019 (Filed With SEC on November 12, 2019)
License Agreement, dated November 4, 2018, between the Company and REGENXBIO Inc (Filed With SEC on March 18, 2019)
Offer Letter, dated February 11, 2019, by and between Abeona Therapeutics Inc. and Joo Siffert, M.D (Filed With SEC on February 13, 2019)
Offer Letter, dated January 8, 2019, by and between Abeona Therapeutics Inc. and Christine Berni Silverstein (Filed With SEC on January 10, 2019)